Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jul 11, 2024 11:21am
169 Views
Post# 36128353

RE:RE:RE:RE:Murky sales report imo

RE:RE:RE:RE:Murky sales report imoIt would be amazing if they were able to maintain sales at the $22 million level seen in the 2Q as Palin suggested following the benefit from the inventory restocking. Also, they need to average $24.3 million in sales over the last two quarters in order to meet the low end of gudiance. Nothing they have shared would indicate we should expect two consecutive simultaneous record sales quarters. Trogarzo sales are slowly dwindling and Egrifta sales are good but likely not that good. 

My guerss is they hope to do an acquisition and they will reset guidance at that point as it will be a bit buried in the details of the acquisition so they hope it will be harder to notice. 

All that being said, the quarter was a good one and there is real hope for the company to do an acquisition, finally; renegotiate their debt with Marathon or do a new debt financing deal to pay off the $40 million first tranche at better terms, get F8 approved and hopefully have some good news on TH1902 that leads to rewarding partnership deals. 
<< Previous
Bullboard Posts
Next >>